introduction: involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. due to several limitations of other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy; bone-seeking radiopharmaceuticals have an important role in palliation of pain from bone metastases. although th...

Background The aim of this study was to evaluate the palliative efficacy of localized external radiotherapy (RT) combined with systemic radionuclide (RN) therapy in patients who had multiple painful osseous metastases of different primary origins. Methods Thirty-three patients initially local external radiotherapy was delivered to the most symptomatic region in all patients. Then they receive...

Designing ideal radiopharmaceuticals for use as bone pain palliatives require the use of a moderate energy β emitter with a stable carrier molecule. Cyclic polyaminophosphonate ligands are known to form complexes with higher thermodynamic stability and kinetic inertness. The present study therefore envisages the use of a few moderate energy β emitters, viz. Lu (T1/2 = 6.71 d, Eβmax= 497 keV), S...

The purpose of the present work was to introduce 141Ce-EDTMP as a novel potential future pain palliative agent to patients suffering from disseminated skeletal metastases and diagnostic imaging radioisotope as well. Cerium-141 [T1/2 = 32.501 days, Eβ (max) = 0.580 (29.8%) and 0.435(70.2%) MeV, Eγ = 145.44 (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of ...

introduction:targeted radionuclide therapy (trt) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. trt is generally performed with a single radionuclide. in this study we investigated the feasibility of combined trt with a high-energy beta emitter (153sm) and a low energy beta emitter (177lu) in wistar rats. methods: the cocktail complex of...